Home > Resources > Whitepapers > TUBERCULOSIS Diagnostics Technology Landscape

TUBERCULOSIS Diagnostics Technology Landscape

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned.

Spotlight

KlinEra Global Services

Since 2005, KlinEra has partnered with some of the largest pharmaceutical, biotech and device companies, providing innovative and customized clinical trial and research services.

OTHER WHITEPAPERS

How to improve manufacturing process efficiency to increase speed-to-market

whitePaper | November 18, 2022

Research by McKinsey on the operational practices of more than 25 global pharmaceutical manufacturers found that the top companies are more than twice as productive as their counterparts.

Discovering Effective Strategies for Sales and Marketing in the Face of Reduced Access to Oncologists

whitePaper | January 15, 2023

Oncology breakthroughs are currently fueling significant growth in the market, as well as the competition between pharmaceutical brands for market share. As increasingly individualized cancer treatments become available,

2022 Global Life Sciences Outlook

whitePaper | January 3, 2022

While valuations for the life sciences sector in this past year have been mixed, the underlying performance and outlook for the

Addressing Viral Pandemics Such as COVID-19 Using the Carterra® LSA

whitePaper | January 21, 2023

Emerging Diseases Require New Tools Medicines to treat and prevent infectious diseases cover a broad range of modalities from dosed therapeutics to vaccines. Biotherapeutics require a detailed knowledge of binding sites, or epitopes, on their respective antigens.

Global Use of Medicines 2023

whitePaper | January 18, 2023

Reaching a post-pandemic era is an alluring prospect for almost everyone around the world after the disruptions of the past three years.

Pharma 2020: Marketing the future. Which path will you take?

whitePaper | August 8, 2021

If Pharma is to create a new marketing and sales model that is fit for 2020, it will have to begin by analysing its own value chain to identify opportunities for working more closely with healthcare payers and providers. It will, for example, have to collaborate much more closely with payers (be they governments, health insurers, employers or patients) to ensure that it develops medicines which have real social and economic value.